Compare Capri Holdings Ltd (CPRI) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Capri Holdings Ltd vs Viatris Inc — how do they compare? Capri Holdings Ltd trades at $14.54 (market cap $1.67B), while Viatris Inc trades at $17.35 (market cap $20.03B). The key difference: Viatris Inc is far larger — about 12× Capri Holdings Ltd's market cap, and Viatris Inc pays a 2.75% dividend while Capri Holdings Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold Capri Holdings Ltd for 41 Days and Viatris Inc for 57 Days on average.
| CPRI | VTRS | |
|---|---|---|
Market Cap | $1.67B | $20.03B |
Volume | 3,722,279 | 14,109,977 |
Sector | Consumer Cyclical | Health |
52-Week High | $27.66 | $18.27 |
52-Week Low | $12.71 | $9.74 |
Typical Hold Time | 41 Days | 57 Days |
Enterprise Value | $2.95B | $32.15B |
Dividend Yield | — | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CPRI trades at $14.44, down 1.57% today, with a bearish technical outlook despite recent earnings beats. The stock shows mixed signals with strong profitability metrics (62.71% gross margin, 252.89% ROE) but concerning fundamental trends including declining revenue from $5.7B in 2022 to $4.4B in 2025 and a significant net loss of -$1.18B. Recent news highlights management's focus on brand revitalization and second-half growth expectations for Michael Kors and Jimmy Choo brands.
The investment case balances attractive valuation (P/S 0.51) against substantial operational challenges. Analyst consensus leans neutral with a $20.57 price target representing 42% upside, but investors face risks from continued revenue declines, high debt levels, and the ongoing Michael Kors turnaround execution. The stock offers potential value if management's growth initiatives gain traction in the second half of 2026.
Viatris (VTRS) trades at $17.49, down 0.29% with a bullish technical signal supported by moving averages and oversold RSI levels. The company shows consistent earnings beats with Q2 2026 EPS of $0.69 exceeding expectations, while maintaining strong operational cash flow of $2.32B in 2025. Recent developments include FDA approval for WAKIX in Japan and continued recognition as a top employer.
Despite negative net margins, Viatris demonstrates improving cash flow trends and strategic portfolio optimization. The stock offers 27% upside to consensus price target of $22.17, though investors face risks from debt levels and competitive pressures in the generic drug market. Deleveraging progress and pipeline advancements support potential re-rating.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Capri Holdings Ltd
Michael Kors, Versace, and Jimmy Choo are the brands of Capri Holdings, a marketer, distributor, and retailer of upscale accessories and apparel. Kors, Capri's largest brand, offers handbags, footwear, and apparel through more than 800 company-owned stores, wholesale, and e-commerce. Versace (acquired in 2018) is known for its ready-to-wear luxury fashion, while Jimmy Choo (acquired in 2017) is best known for women's luxury footwear. John Idol has served as CEO since 2003.
Read more on CPRI →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
